Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Efficacy and Exposure of Subcutaneously Administered NNC0365-3769 (Mim8) Prophylaxis in Children With Haemophilia A With or Without FVIII Inhibitors

NCT05306418 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT05306418
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05306418 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Efficacy and Exposure of Subcutaneously Administered NNC0365-3769 (Mim8) Prophylaxis in Children With Haemophilia A With or Without FVIII Inhibitors
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
April 4, 2022
Completion date
November 13, 2024
Enrollment
70 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

haemophilia a with or without inhibitors